Emcure Pharmaceuticals Ltd (EMCURE) is currently trading at 1,862.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Emcure Pharmaceuticals is a diversified Indian pharmaceutical company that develops, manufactures and commercially markets a broad range of products across India and 80+ international markets, with capabilities spanning orals, complex injectables, biologics, chiral molecules and novel drug delivery platforms and a FY26 revenue run‑rate above USD 1 billion. Emcure delivered robust FY26 operating performance: INR 92,035 Mn revenue (+16.6% YoY), EBITDA of INR 17,886 Mn (19.4% margin, +80 bps YoY) and PAT of INR 9,413 Mn (+33.1% YoY), reflecting operational leverage and an adjusted PAT improvement of 40.9% that underpins improving return metrics and a 23.7% RoCE in FY26. The company combines a scaled domestic branded generics franchise — with 19 of top 20 brands ranked among the top three and a 60%+ chronic mix — and differentiated international platforms in Europe, Canada and RoW focused on complex injectables, biosimilars and ARVs, which together support diversified growth across geographies and channels. Emcure’s strategic agenda is clearly articulated: deepen chronic and specialty domestic franchises, scale differentiated international portfolios through front‑end expansion and in‑licensing, and translate R&D platforms into commercial launches across obesity, ophthalmology, oncology, anti‑infectives and HIV, with partnerships and M&A as accelerators.

Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹1,307.50 and a high of ₹2,101.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Emcure Pharmaceuticals Ltd has a market capitalization of approximately 35,357.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.70 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 35,357.32 Cr, Emcure Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Emcure Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 34.70. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations rose 22.8% year-on-year to about ₹2,580.5 crore, and consolidated net profit rose 36.2% to about ₹292.5 crore for the June 2026 quarter.

Emcure acquired the remaining 12.05% stake in Gennova, taking its holding from 87.95% to 100%.

Bain Capital, via its affiliate BC Investments IV Ltd, sold its remaining roughly 1% stake in Emcure Pharma, completing its exit.

Kotak Mahindra Mutual Fund bought 36 lakh shares, or 1.89% stake, in Emcure Pharmaceuticals via June 9 transactions.